NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumorsChristoph Schulz, Volker Heinemann, Volker Kunzmann et al.|International Journal of Cancer|2014Cited by 126
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJobst C. von Einem, Dominik Paul Modest, Thomas Kirchner et al.|Journal of Cancer Research and Clinical Oncology|2014Cited by 112
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306Sebastian Stintzing, Volker Heinemann, Thomas Kirchner et al.|Annals of Oncology|2012Cited by 110
Prognostic value of cetuximab‐related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study GroupSebastian Stintzing, Volker Heinemann, Thomas Kirchner et al.|International Journal of Cancer|2012Cited by 81